Introduction
Patients with advanced-stage mycosis fungoides (MF)/Sézary syndrome (SS) are characterized by skin tumours (stage IIB) or erythroderma (stage III); blood (stage IVA1), nodal (stage IVA2) or visceral involvement (stage IVB) may occur [1] [2] [3] [4] [5] . The prognosis of advanced-stage disease is poor, with 5-year overall survival (OS) rates from 40% to 70% in tumor-stage or erythroderma, down to 15%-40% for extracutaneous involvement [6] [7] [8] [9] [10] . Thus, these patients have an unmet clinical need of effective treatments. However, the rarity of the disease and the lack, until recently, of established criteria for staging and response evaluation [11] impaired the development of prospective clinical trials and no treatments have been shown to improve survival. International guidelines detail treatment options for the different stages without recommending any treatment order due to lack of comparative trials [12] [13] [14] [15] . The current therapeutic strategies in leading centers worldwide have been influenced therefore by consensus and institutional preference, geographical regulatory status and availability of treatment modalities. No data are available as to therapy heterogeneity across the world, and what impact (if any) this variability may have on survival.
In 2012, members from the Cutaneous Lymphoma Task Force (CLTF) of the European Organization for Research and Treatment of Cancer (EORTC), the International Society for Cutaneous Lymphoma (ISCL) and the United Cutaneous Lymphoma Consortium (USCLC) established the Cutaneous Lymphoma International Consortium (CLIC), with the aim of developing collaborative researches, producing meaningful prospective studies and improving the understanding of CTCL clinical and biological characteristics. As first collaborative step, retrospective studies were undertaken to test the potential of collecting large clinical data sets. The first CLIC project analyzed prognostic markers on OS in 1394 advanced-stage MF/SS patients [16] , identifying as independent unfavorable variables stage IV, age >60 years, large-cell transformation and increased LDH values and combining them in a prognostic index model (low-, intermediate-and high-risk group). As a second step, the participating centers were asked to provide treatment modalities for advanced-stage MF/SS patients. The aims of this second CLIC study, reported in this paper, were to analyze the global pattern of care worldwide, the distribution of treatments according to geographical areas (USA versus non-USA) and whether the heterogeneity of approaches can have potential impact on OS.
Patients and methods

Patient selection
Patients were collected retrospectively from 21 international centers (14 European, 4 USA, 1 Australian, Brazilian, and Japanese). Inclusion criteria were: diagnosis from January 2007 to December 2014, clinical stage IIB or higher [5] (Table 1) .
MF diagnosis was confirmed according to ISCL/EORTC criteria [2] [3] [4] [5] . All the patients were re-classified according to the new ISCL/EORTC classification [2] [3] [4] [5] 17] . All patients had a detailed physical exam for the determination of the extent and severity of skin involvement and imaging study to assess nodal or visceral disease. The pathologic diagnosis was based on the biopsy results reported by institution hospital registries. Nodal/visceral involvement was defined in the presence of pathological confirmation.
Data collected
Data retrieved for each patient were: demographics, TNMB staging at initial diagnosis of advanced-stage disease, treatment modalities up to the 10 th treatment line whenever performed, total number of treatment lines, start and end date for each treatment; survival status at last contact; date of death or of last contact for patients alive. Treatment response data were not collected due to the absence of homogeneous response evaluation criteria and difficulties to define retrospectively response according to the recent consensus criteria [11] .
Statistical analysis
Continuous variable distributions were compared through the Wilcoxon rank-sum test. The possibility of an association between categorical variables was assessed through the Fisher's exact test. The non-parametric test for trend across ordered groups developed by Cuzick [18] was used to compute the test for trend for the prevalence of use of different treatments in consecutive therapy lines. A logistic regression model was fitted to data with the type of treatment as the outcome and geographical area (USA/non-USA), stage (categorical variables with six levels: IIB, IIIA,  IIIB, IVA1, IVA2, IVB) , and age at diagnosis as predictors.
Overall survival (OS) was established from diagnosis to death or to the last contact date or to the end of follow-up, whichever occurred first, counting all deaths as events. Life-table survival estimates were derived by the Kaplan-Meier method by age, TNMB stage and geographical site, and compared using the Mantel's stratified log-rank test [19] . A multivariable Cox proportional-hazards regression model was used to estimate the association between mortality for all causes and the variables above [20] . The proportionality assumption was assessed by examination of Schoenfeld residuals, giving no reason for violation.
In order to investigate the effects of the first treatment line, we estimated the cumulative mortality curves treating the change of therapy class as a competing risk event. Cumulative incidence of both therapy change and death by age, TNMB stage, geographical site and first treatment line were compared using a multivariable competing risk regression model for the sub-distribution hazards fitted to data according to the method of Fine and Gray [21] .
Statistical analyses were performed with Stata 13 (StataCorp LP, College Station, TX).
Results
Patient cohort characteristics
Among 853 patients included, 40.4% were from USA centers, with the majority of the remaining from Europe. Median followup time was 1.7 years. Less than one-third of patients (29%) were followed for <1 year, whereas 43% and 27% were followed for at least 2 or 3 years, respectively.
There was a male preponderance (male/female: 1.61) with a median age at advanced-stage diagnosis of 64 years (range: 8-90), without differences between USA and non-USA centers. Stage IIB was the most frequent at first diagnosis of advanced-stage disease (35.4%). There was a higher percentage of stage III in non-USA centers, while stage IVB was more frequently in USA (P < 0.001) ( Table 2) .
Treatment lines
The median number of treatment lines was two per patient in both USA and non-USA centers, with a remarkable number of patients receiving multiple treatments (36% 4 or more; 2% between 10 and 24). Table 3 shows the distribution of treatments in time. The most commonly used first approach was photopheresis either alone (10%) or in combination (8.6%), followed by bexarotene and phototherapy. The most frequently used chemotherapies as firstline treatment were gemcitabine (6.2%) and polychemotherapy (5.3%). Photopheresis was the most frequently used approach also as second-line treatment, while as third line, bexarotene and interferon (IFN) were most widely employed. From the fourth treatment line, histone deacetylase inhibitors (HDACi), polychemotherapy and pegylated doxorubicin were more commonly prescribed. Allogeneic transplantation was not performed in any case as first treatment, but it was most common from the fourth line of treatment (from 4.2% to 6.4% of patients) (test for trend with treatment line: P < 0.0001).
In summary, a statistically significant decrease of use with the number of treatment lines was found for photopheresis, bexarotene and phototherapy, while there was an increase with lines of therapy for poly-chemotherapy, TSEBT, HDACi, pegylated doxorubicin, new target therapies and transplantation (supplementary Figures S1 and S2, available at Annals of Oncology online).
Treatment approaches according to stages
The most frequently used first-line treatment in stage IIB patients was bexarotene followed by local RT, phototherapy, TSEBT and gemcitabine (supplementary Table S1 , available at Annals of Oncology online). Methotrexate was the most commonly used first treatment for stage IIIA, while photopheresis (alone or in combination) for stage IIIB. Photopheresis was also the most common first-line treatment in stage IVA1 followed by IFN and First treatment line distribution according to stage, age and geographical site Figure 1 summarizes first-line treatments used in USA and non-USA centers, while Table 4 shows the odds ratio (OR) of receiving a given first-line treatment according to disease stage, age and geographical site. Phototherapy, alone or in combination, is used less frequently in USA. Photopheresis and bexarotene are significantly associated with the geographical area, being more frequent in USA while IFN, which does not show a statistically significant association with stage, was more frequently prescribed in non-USA centers. HDACi were used in all stages but, as expected, more frequently in USA (FDA approval), while MTX was used predominantly in stage III, without differences between USA and non-USA centers. Compared with USA centers, non-USA centers treat their patients significantly more frequently with chlorambucil also more frequently adopted in elderly patients. No differences were found in poly-CT or pegylated doxorubicin according to geographical areas.
Survival analyses
Two types of analysis were carried out ( Figure 2 and Table 5 ). In the first, the variables age, TNMB stage and geographical site (USA versus non-USA) were included in a Cox regression model, with death due to any cause as the end point. Age and stage showed prognostic significance while geographical site did not show any association with mortality.
In the second analysis, death and therapy change were considered as competing risk events, and the impact of first treatment line on both events was analyzed with a Fine and Gray regression model. Geographical site and stage did not show any prognostic relevance for either outcome, whereas the only statistical significant association was between age and death. Although overall first-line treatment group was not selected as independent prognostic variable, both mono-chemotherapy (SHR ¼ 2.07, 95% CI 1.14-3.78) and poly-chemotherapy (SHR ¼ 1.69, 95% CI 0.61-4.66) showed elevated relative risks of death.
Discussion
In this second CLIC study, the largest cohort of patients presenting with advanced-stage MF/SS (853 cases) with data on treatment collected retrospectively in 21 international centers was analyzed to evaluate the worldwide usage profile of regionally available treatments and potential impact on survival.
The first finding was that treatment approaches are characterized worldwide by a striking heterogeneity with up to 24 different drugs, modalities or combinations used as first-line treatment. Several explanations can lead to this heterogeneity, mainly represented by the rarity of the disease, which impaired the design of randomized clinical trials and thus the development of homogeneous treatment guidelines, and additionally the limited activity of available drugs [15] . This opened the field for treatment algorithms based on institutional preference, skill and equipment of each institute, different regulatory status, availability of treatment modalities, entry to clinical trials and health insurance system. In the future, the identification of new clinical and biological prognostic parameters may help to drive clinical treatment decisions [16, 22] . Disease stage clearly remains an important parameter for treatment decision and TNMB stage was associated with relevant differences in treatment approaches, as expected [12] [13] [14] .
Stage IIB was most frequently treated by skin-directed approaches (phototherapy or radiotherapy), bexarotene and gemcitabine while photopheresis was most commonly used as first-line treatment in SS or erythrodermic MF (stage III and IVA1) and polychemotherapy in stage IVA2/B. There were trends in drug use during the course of the disease with decreased use of photopheresis alone or in combination, bexarotene and phototherapy alone or in combination and conversely, increased use of chemotherapy, target therapies and transplant. These data support a preferential use of immune-modifiers as first line therapy with subsequent use of chemotherapy, targeted therapies or transplant for patients with relapsed/resistant disease. This strategy of using immune-stimulation is solidly based on pre-clinical data, showing the relevance of cancer immuno-surveillance in down-regulating the evolution of the disease [23] , now supported by a number of clinical studies [24] such as the superior outcome of photopheresis when performed as first-line treatment early after diagnosis [25] . The USCLC recommendations [26] highlight that one of the principles for SS treatment is to preserve the immune response, fostering the use of immune-modulatory therapy (particularly as combination therapy) before chemotherapy except in the presence of rapid growth of tumor burden or failure of prior such therapies. The second focus was that there exist significant differences in treatment approaches between USA and non-USA centers. The therapies more frequently prescribed as first-line treatment independent of disease stage distribution are bexarotene and photopheresis in USA while phototherapy, IFN, chlorambucil and gemcitabine for non-USA centers. The same factors that accounted for treatment heterogeneity can partly explain these geographical differences, mirroring different approaches to patient management along with different drug regulatory approvals (HDACi and denileukin diftitox not available outside the USA) and access to new drugs through clinical trials. The major use of photopheresis in USA and gemcitabine in non-USA centers can Table 3 . Distribution of treatments performed in time (percentage of patients treated with that therapy out of the total no. of patients treated in a given treatment line) in the first 10 treatment lines B e x a r o t e n e E C P M e t h o t r e x a t e I n t e r f e r o n L o c a l R T G e m o it a b in e U n k n o w n
P h o t o t h e r a p y P o ly c h e m o t h e r a p y T S E B T E C P p lu s in t e r f e r o n E C P p lu s B e x a r o t e n e H D A C O t h e r r e t in o id s P h o t o t h e r a p y p lu s in t e r f e r o n P e g y la t e d d o x o r u b ic in A le m t u z u m a b P h o t o t h e r a p y p lu s o t h e r r e t in o id s O t h e r m o n o c h e m o t h e r a p y E C P p lu s o t h e r r e t in o id s P h o t o t h e r a p y p lu s b e x a r o t e n e D e n il e u k in d if t it o x
I n t e r f e r o n p lu s o t h e r r e t in o id s P h o t o t h e r a p y p lu s in t e r f e r o n p lu s b e x a r o t e n e B e x a r o t e n e p lu s in t e r f e r o n B r e n t u x im a b O t h e r s E C P p lu s in t e r f e r o n p lu s b e x a r o t e n e E C P p lu s m e t h o t r e x a t e P r a la t r e x a t e E C P p lu s p h o t o t h e r a p y T o p ic a l n it r o g e n m u s t a r d C h lo r a m b u c il Figure 1 . Distribution of first treatment line between USA and non-USA centers. ECP, extracorporeal photochemotherapy; RT, radiotherapy; TSEBT, total-skin-electron-beam therapy; HDAC, histone deacetylase inhibitors.
be driven by the fact that these treatments were originally trialed in USA and Europe, respectively [27] [28] [29] . In USA there were few centers with large volumes while Europe is characterized by many centers each contributing a small number of patients, suggesting a considerable effect of institution 'tradition'. This could explain the preferential use of unexpected drugs such as chlorambucil. The major use of phototherapy outside USA could be related to climate condition with reduced sun exposure in northern Europe countries. The final observation is that the differences in treatment approaches as first-line therapy between USA and non-USA centers did not lead to a statistically significant impact on survival. Indeed, stage and age were independent OS predictors while the geographical site (USA versus non-USA) was not. The key outcomes of the competing risk event approach (Fine and Gray model) were that patients initially treated with polychemotherapy are those that most frequently change therapy; even if overall first-line treatment group was not selected as independent prognostic variable for mortality of therapy change, both monochemotherapy (SHR ¼ 2.07) and polychemotherapy (SHR ¼ 1.69) showed elevated relative risks of death, showing a negative impact of chemotherapy on disease course when performed as first line therapy. These estimates are adjusted for stage and geographical site but cannot address the potential confounder of tumor bulk or biology which is not adequately reflected by stage. Interpretation of these findings should be taken in the context that no chemotherapy regimen has been shown to improve survival given their modest clinical activity, with responses usually of short duration (6-9 months) [12-14, 30, 31] . Moreover, it has been reported that time-to-next-treatment [15] is significantly shorter for single-or multi-agent chemotherapy (median: 3.9 months) with respect to interferon (8.7 months) and HDACi (4.5 months). The results of the present study suggest that chemotherapy should be reserved only after failure of previous approaches and where other options are exhausted.
The main limitation of this study lies in its retrospective collection of information. Missing data and insufficient information to avoid confounding by indication (estimate the effects of treatments on prognosis not accounting properly for stage and disease status, which in turn are determinant of the treatment and prognosis) must be kept in mind to avoid over interpretation. Moreover, the absence of data maintained consistently and differences in response tools and criteria, did not allow us to provide response duration or quality of life information.
In conclusion, this large multicenter retrospective study shows a substantial heterogeneity of treatment approaches in advanced MF/SS between USA and non-USA centers, even if these differences do not influence survival outcome. The sequence of treatments could play a role since we observed that chemotherapy, when used as first treatment, is associated with a higher risk of death and/or change of therapy. This retrospective study highlighted the importance of currently ongoing prospective CLIC studies which will attempt to link treatment data with the prognostic models such as those developed in the first CLIC study [16] . 
